Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.41 |
| ▸ | ATP4A | P20648 | 2/20 | 0.39 |
| ▸ | ATP4B | P51164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224380 | 0.87 | MAPK11 (0.50) | BAZ2AHPGDSALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL9984662 | 0.83 | ATP4A (0.44) | HPGDSATP4AATP4BALDH1A1L3MBTL1 | |
| SCHEMBL2218485 | 0.81 | ATP4A (0.47) | HPGDSATP4AATP4BALDH1A1L3MBTL1 | |
| Fumaric Acid SCHEMBL8687199 | 0.78 | BAZ2A (0.48) | BAZ2AHPGDSCHEK1CCNA2CDK2 | |
| Fumaric Acid SCHEMBL8687194 | 0.78 | BAZ2A (0.48) | BAZ2AHPGDSCHEK1CCNA2CDK2 | |
| SCHEMBL2636212 | 0.78 | HPGDS (0.52) | BAZ2AHPGDSALDH1A1L3MBTL1GAA | |
| SCHEMBL2225122 | 0.77 | BAZ2A (0.43) | BAZ2AHPGDSCHEK1CCNA2CDK2 | |
| Bromide SCHEMBL12805678 | 0.77 | BAZ2A (0.43) | BAZ2AHPGDSCHEK1CCNA2CDK2 | |
| SCHEMBL14320438 | 0.75 | RAB9A (0.48) | HPGDSATP4AATP4BALDH1A1L3MBTL1 | |
| SCHEMBL7258912 | 0.73 | BAZ2A (0.46) | BAZ2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BAZ2A 2402/4885HPGDS 2974/4885CHEK1 346/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BAZ2A 1900/4885HPGDS 1603/4885CHEK1 189/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BAZ2A 2402/4885HPGDS 2974/4885CHEK1 346/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | BAZ2A 2402/4885HPGDS 2974/4885CHEK1 346/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | BAZ2A 2307/4885HPGDS 3534/4885CHEK1 308/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | BAZ2A 2182/4885HPGDS 2788/4885CHEK1 324/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | BAZ2A 2182/4885HPGDS 2788/4885CHEK1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.